Market closed

Agenus/$AGEN

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Agenus

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Ticker

$AGEN
Trading on

Industry

Biotechnology

Employees

389

Agenus Metrics

BasicAdvanced
$88M
Market cap
-
P/E ratio
-$10.97
EPS
1.39
Beta
-
Dividend rate
$88M
1.39
$19.69
$2.50
577K
0.185
0.166
-20.471
-29.016
-0.73%
-21.95%
120.92%
0.464
-0.28
-0.25
-0.435
59.00%
-30.79%
-19.42%
215.29%

What the Analysts think about Agenus

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Agenus stock.

Agenus Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Agenus Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AGEN

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Agenus stock?

Agenus (AGEN) has a market cap of $88M as of December 04, 2024.

What is the P/E ratio for Agenus stock?

The price to earnings (P/E) ratio for Agenus (AGEN) stock is 0 as of December 04, 2024.

Does Agenus stock pay dividends?

No, Agenus (AGEN) stock does not pay dividends to its shareholders as of December 04, 2024.

When is the next Agenus dividend payment date?

Agenus (AGEN) stock does not pay dividends to its shareholders.

What is the beta indicator for Agenus?

Agenus (AGEN) has a beta rating of 1.39. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.